About: NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.53 (+2.92%)
NXTC NASDAQ NextCure Inc
NextCure Inc share price
Atividade de preço de NXTC
Último preço
$ 6,530
Variação (24h)
0,19 USD (2,92%)
Volume
58.25K
Volume (média 4 sem.)
-
Abertura
$ 6,06
Variação do dia
$ 5,84 - $ 6,66
Fechamento anterior
$ 6,34
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
NXTC price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals